Evidence map›Paper›PMID 33968653›Full record

ArticleTranslational andrology and urology2021

The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.

Lara Kremer, Melanie von Brandenstein, Maike Wittersheim, Barbara Koeditz, Pia Paffenholz, Martin Hellmich, David Pfister, Axel Heidenreich, Tim Nestler

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. MicroRNAs in Testicular Germ Cell Tumors: The Teratoma Challenge.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lara KremerDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Melanie von BrandensteinDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Maike WittersheimInstitute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Barbara KoeditzDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Pia PaffenholzDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Martin HellmichInstitute of Medical Statistics and Computational Biology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
David PfisterDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Axel HeidenreichDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Tim NestlerDepartment of Urology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
University of Cologne · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo identify a combination of microRNAs (miRNA) to differentiate between viable tumor (V) or teratoma (T) and necrosis/fibrosis (N) in pcRPLND specimens of metastatic germ cell tumor (GCT) patients with residual masses ≥1 cm after chemotherapy. Biomarker guided therapy could reduce overtreatment with pcRPLND in patients with only N.

methodsWe selected 48 metastatic GCT patients who had undergone pcRPLND. V, pure T and N was shown in the resected tissue of 16 patients, respectively. Of these areas total RNA was isolated and miRNA expression was analyzed for miR-371a-3p, 375-3p, and 375-5p using qPCR. ROC analysis was performed for each miRNA and for all combinations in order to determine the discriminatory capacity of V and T

resultsOn comparing V

conclusionsBy combining miR-371a-3p and miR-375-5p in pcRPLND tissue samples V and T could be distinguished from necrosis/fibrosis with great accuracy. This combination of miRNAs might serve as new biomarker in the future, in order to spare miRNA-negative patients from pcRPLND. However, further studies analyzing patient's serum are needed to confirm the clinical impact of these biomarkers.

Indexed as

germ cell tumor (GCT)miR-371-3pmiR-375post-chemotherapy lymph node dissectiontesticular cancer

Identifiers

PMID33968653
PMCPMC8100847
OpenAlexW3147074979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.